O'Connor-Projects

O'Connor-Projects

Projects

Mapping the genetics of drug resistance in colorectal cancer with high-throughput knockout technology

While some patients with metastatic colorectal cancer benefit from drugs that inhibit specific growth factor signaling pathways, most do not. We are using whole-genome mutagenesis technology (CRISPR/Cas9) to identify genetic mutations that can give rise to drug resistance in colorectal cancer cells. By deep-sequencing of the resulting genetic libraries, we have identified multiple gene mutations that contribute to resistance against drugs targeting the epidermal growth factor receptor. The genes identified in this study may improve our capacity to predict the response of colorectal cancer patients to specific therapeutic regimes, and facilitate a more personalized approach to the treatment of cancer.